Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul:128:104443.
doi: 10.1016/j.jcv.2020.104443. Epub 2020 May 16.

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19

Ali Hassoun  1 , Elizabeth Dilip Thottacherry  2 , Justin Muklewicz  3 , Qurrat-Ul-Ain Aziz  4 , Jonathan Edwards  5
Affiliations
Comment

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19

Ali Hassoun et al. J Clin Virol. 2020 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors report no conflicts of interest.

Comment on

References

    1. Li Q., Guan X., Wu P. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New England Journal of Medicine. 2020 - PMC - PubMed
    1. Liu B., Li M., Zhou Z., Guan X., Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Journal of Autoimmunity. 2020 102452. - PMC - PubMed
    1. Tocilizumab in COVID-19 Pneumonia (TOCIVID-19). https://ClinicalTrials.gov/show/NCT04317092.
    1. Fu B., Xu X., Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? Journal of Translational Medicine. 2020;18(1):1–5. - PMC - PubMed
    1. Luo P., Liu Y., Qiu L., Liu X., Liu D., Li J. Tocilizumab treatment in COVID‐19: a single center experience. Journal of Medical Virology. 2020 - PMC - PubMed

Substances